St. George's already had a higher than average intake of students with non-European names. Collier was initially shunned within the institution and denied a due professorship. As attitudes changed, his position improved; he was promoted to professor and eventually the medical school publicly thanked him. He discussed his experience in an article in the British Medical Journal in 1999 when he recalled that he "was ostracised, became invisible, told I [he] had brought the organisation into disrepute”. Changes in admissions procedures to institutes of higher education have since been made throughout the UK and Collier has since been acknowledged for contributing towards greater equality in recruitment practices. National policy In his national policy work, he raised awareness of how drugs are priced, brought to the market and regulated, in addition to how they are evaluated, licensed and promoted, and how drug safety advice is produced and revised. He has spoken of the "excesses of industry", despite several general practitioners finding the pharmaceutical educational material they received as useful. In 1993, he was appointed lead adviser on medicines to Parliament's Health Select Committee. In 1998, he was appointed to the Medicines Commission. He was one of the specialist scientific advisors who helped change the way drugs are priced and bought by the NHS. In 2007, Collier contributed to the report by the Office of Fair Trading, which recommended that drug prices to the NHS should be in accordance with their clinical value. In addition, he worked to ensure that members of governmental advisory committees published their conflicts of interest. Drug and Therapeutics Bulletin Collier began working for the Drug and Therapeutics Bulletin (DTB) in 1969. In 1972, he became its deputy editor and member of the DTB's Advisory Council, after at first being associate editor. He succeeded Andrew Herxheimer, who founded the bulletin, as its editor in 1992, and over the following 12 years shaped the bulletin in response to new challenges of the time, including the growth in electronic information, evidence-based guidelines, a growing demand to engage the public and healthcare workers and the establishment of the National Institute for Clinical Excellence (NICE). Drug safety In 1985, he complained to the Association of the British Pharmaceutical Industry that of 28 drug advertisements in the November 1985 issue of the British Medical Journal, 11 were in breach of the Medicines Act of 1968. Known to frequently question evidence and arguments accepted